INO-A002 is a DNA-encoded monoclonal antibody (dMAb™) technology candidate.
INO-A002 is indicated to prevent or treat the Zika virus infection.
The vaccine will be delivered as an intramuscular (IM) injection followed by electroporation with the CELLECTRA® 2000 device.
When delivered directly into the body, the genetic codes provided by the synthetic dMAbs, instruct the body's cells to become the factory which manufactures the therapeutic antibody products.
February 20, 2019, Inovio Pharmaceuticals, Inc. in collaboration with The Wistar Institute and the University of Pennsylvania announced that the first subject was dosed as part of the first-ever human study of Inovio's DNA-encoded monoclonal antibody (dMAb™) technology.
Clinical Trial NCT03831503: A Study of INO-A002 in Healthy Dengue Virus-naive Adults
This Phase 1, open-label, single center, is a dose escalation study to evaluate the safety, tolerability and pharmacokinetic profile of dMAb-ZK190 following delivery of INO-A002 with Hylenex® recombinant delivered IM followed by EP in healthy adult Dengue naïve volunteers ages 18-60 years.
This dose escalation trial will enroll up to 24 healthy volunteers who will receive up to four doses of INO-A002.
Participants (n=6 per cohort) will be administered INO-A002 at four dose levels: 0.5, 1, 2, and 4 mg DNA/dose.
The trial is led by Pablo Tebas, M.D., Professor of Medicine at the Hospital of the University of Pennsylvania.